A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry

Chinese Medical Journal

Volumn 124, Issue 9, 2011, Pages 1367-1373

  Lian, Jiang shan ^a   Liu, Wei ^a   Hao, Shao rui ^a   Guo, Yong zheng ^a   Huang, Hai jun ^a   Chen, De ying ^a   Xie, Qing ^a   Pan, Xiao ping ^a   Xu, Wei ^a   Yuan, Wen xia ^a   Li, Lan juan ^a   Huang, Jian rong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Liquid chromatography; Liver cirrhosis; Metabonomics; Multivariate analysis

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; HYPOXANTHINE; LYSOPHOSPHATIDYLCHOLINE; METABONOME; MYRISTAMIDE; OLEAMIDE; STEARAMIDE; UNCLASSIFIED DRUG;

ADULT; ALCOHOL LIVER CIRRHOSIS; ANALYTIC METHOD; ARTICLE; CHEMOMETRICS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISCRIMINATION ANALYSIS; EARLY DIAGNOSIS; FEMALE; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; METABONOMIC; PARTIAL LEAST SQUARES REGRESSION; PRINCIPAL COMPONENT ANALYSIS; PROSPECTIVE STUDY; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; ALCOHOLS; CHROMATOGRAPHY, LIQUID; FEMALE; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS;

EID: 79955939938     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.09.018     Document Type: Article

References (36)

1. Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am 2009; 93: 787-799, vii.
2. Myers RP, Shaheen AA, Hubbard JN, Kaplan GG. Characteristics of patients with cirrhosis who are discharged from the hospital against medical advice. Clin Gastroenterol Hepatol 2009; 7: 786-792.
3. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health 2003; 27: 209-219.
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
5. Liu J, Fan D. Hepatitis B in China. Lancet 2007; 369: 1582-1583.
6. Cochrane J, Chen H, Conigrave K, Hao W. Alcohol use in China. Alcohol Alcohol 2003; 38: 537-542.
7. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
8. Nicholson JK, Holmes E, Lindon JC, Wilson ID. The challenges of modeling mammalian biocomplexity. Nat Biotechnol 2004; 22: 1268-1274.
9. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004; 22: 245-252.
10. Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007; 8: 1243-1266.
11. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009; 5: 868-876.
12. Xue R, Dong L, Wu H, Liu T, Wang J, Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med 2009; 47: 305-310.
13. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440: 1073-1077.
14. Jiang H, Peng J, Zhou ZY, Duan Y, Chen W, Cai B, et al. Establishing 1H nuclear magnetic resonance based metabonomics fingerprinting profile for spinal cord injury: a pilot study. Chin Med J 2010; 123: 2315-2319.
15. Chen MJ, Ni Y, Duan HQ, Qiu YP, Guo CY, Jiao Y, et al. Mass spectrometry-based metabolic profiling of rat urine associated with general toxicity induced by the multiglycoside of Tripterygium wilfordii Hook. f. Chem Res Toxicol 2008; 21: 288-294.
16. Yu K, Sheng GP, Sheng JF, Chen YM, Xu W, Liu XL, et al. A metabonomic investigation on the biochemical perturbation in liver failure patients caused by hepatitis B virus. J Proteome Res 2007; 6: 2413-2419.
17. Zelena E, Dunn WB, Broadhurst D, Francis-McIntyre S, Carroll KM, Begley P, et al. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal Chem 2009; 81: 1357-1364.
18. Michopoulos F, Lai L, Gika H, Theodoridis G, Wilson I. UPLC-MS-based analysis of human plasma for metabonomics using solvent precipitation or solid phase extraction. J Proteome Res 2009; 8: 2114-2121.
19. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158: 227-233.
20. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007; 41: 616-623.
21. Ikeda H, Nagashima K, Yanase M, Tomiya T, Arai M, Inoue Y, et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003; 285: G880-G886.
22. Chiang JY. Regulation of bile acid synthesis. Front Biosci 1998; 3: d176-d193.
23. Vlahcevic ZR, Pandak WM, Stravitz RT. Regulation of bile acid biosynthesis. Gastroenterol Clin North Am 1999; 28: 1-25, v.
24. Nunes de Paiva MJ, Pereira Bastos de Siqueira ME. Increased serum bile acids as a possible biomarker of hepatotoxicity in Brazilian workers exposed to solvents in car repainting shops. Biomarkers 2005; 10: 456-463.
25. Ramm GA, Shepherd RW, Hoskins AC, Greco SA, Ney AD, Pereira TN, et al. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology (Baltimore, Md) 2009; 49: 533-544.
26. Krähenbähl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology 1997; 25: 148-153.
27. Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, Benatti P, et al. Carnitine: an osmolyte that plays a metabolic role. J Cell Biochem 2000; 80: 1-10.
28. Mueller GP, Driscoll WJ. Biosynthesis of oleamide. Vitam Horm 2009; 81: 55-78.
29. Boger DL, Henriksen SJ, Cravatt BF. Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des 1998; 4: 303-314.
30. Hiley CR, Hoi PM. Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? Cardiovasc Drug Rev 2007; 25: 46-60.
31. Zeng T, Xie KQ. Ethanol and liver: recent advances in the mechanisms of ethanol-induced hepatosteatosis. Arch Toxicol 2009; 83: 1075-1081.
32. Siegmund SV, Brenner DA. Molecular pathogenesis of alcohol-induced hepatic fibrosis. Alcohol Clin Exp Res 2005; 29: 102S-109S.
33. Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Buttner R, et al. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res 2009; 19: 996-1005.
34. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007; 132: 1955-1967.
35. Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J 2008; 416: 219-230.
36. Martin-Vilchez S, Sanz-Cameno P, Rodriguez-Munoz Y, Majano PL, Molina-Jimenez F, Lopez-Cabrera M, et al. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 2008; 47: 1872-1883.